Nimbus Apollo

About:

Nimbus Apollo, Inc. research and develops drugs that treats non-alcoholic steatohepatitis.

Website: https://www.nimbustx.com/

Twitter/X: NimbusTx

Top Investors: Lightstone Ventures, Pfizer Venture Investments

Description:

Previously a sub-organization of Nimbus Therapeutics, the Nimbus Apollo program includes the lead candidate NDI-010976, an ACC inhibitor, and other preclinical ACC inhibitors for the treatment of non-alcoholic steatohepatitis (NASH), and for the potential treatment of hepatocellular carcinoma (HCC) and other diseases. NDI-010976 was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) in February 2016 and Phase 1 data for the compound will be presented next month during an oral session at The International Liver Congress 2016, the annual meeting of the European Association for the Study of the Liver (EASL).